Checkpoint Therapeutics Stock Price - CKPT

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Checkpoint Therapeutics Inc CKPT NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 1.79 0.00 0.00 0.00 1.79 19:00:00
Bid Price Ask Price Spread Spread % News
1.70 1.90 0.20 10.53% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Checkpoint Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 68.01M 38.00M $ -36.37M -1.28 - 35.16M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 7.50%

more financials information »

Checkpoint Therapeutics News

Loading Messages....

Latest CKPT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CKPT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.831.901.721.7827,678-0.04-2.19%
1 Month1.932.101.701.8839,775-0.14-7.25%
3 Months3.033.341.702.3256,972-1.24-40.92%
6 Months4.314.871.703.0688,033-2.52-58.47%
1 Year2.385.201.503.1680,154-0.59-24.79%
3 Years10.5010.501.503.6673,971-8.71-82.95%
5 Years10.5010.501.503.6673,971-8.71-82.95%

Checkpoint Therapeutics Description

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.